The neurobiology of attention-deficit/hyperactivity disorder.
Chamberlain
Samuel R
SR
Robbins
Trevor W
TW
Sahakian
Barbara J
BJ
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D001921:Brain / Q000503:physiopathology*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002531:Cerebellum / Q000503:physiopathology; D002648:Child; D003342:Corpus Striatum / Q000503:physiopathology; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000453:epidemiology / Q000517:prevention & control; D004298:Dopamine / Q000502:physiology; D005625:Frontal Lobe / Q000503:physiopathology; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use; D009415:Nerve Net / Q000503:physiopathology; D009638:Norepinephrine / Q000502:physiology; D011437:Propylamines / Q000627:therapeutic use; D009435:Synaptic Transmission / Q000502:physiology
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride; D004298:Dopamine; D009638:Norepinephrine